COVID-19 Panel Gilead Ties

October 25: This corrupt panel nixes all treatments competing against Gilead’s remdesivir. It even recommends against prophylaxis – any prophylaxis!

September 22: H. Clifford Lane, a Co-Chair of the Panel, is a co-author of the fraudulent NIAID study of Remdesivir (Beigel et al., May 22), which served the Panel as an excuse to recommend the use of Remdesivir. He has not disclosed co-authorship. Undisclosed ties of two other Co-Chairs (Roy M. Gulick and Henry Masur) to Gilead are listed below. Continue reading COVID-19 Panel Gilead Ties

NEJM Day: Boosting RDV, Attacking HCQ

2020-10-18 update: even the SOLIDARITY trial, conducted by pro-Gilead WHO, found Remdesivir ineffective for COVID-19.

On October 8, the New England Journal of Medicine fired a new salvo against Hydroxychloroquine. It published the results of a tragicomic RECOVERY trial, and the “final report” of NIAID study of Gilead’s Remdesivir (Remdeathsivir). 

The fake news media treats this RECOVERY paper as news, and claims it proves that HCQ does not help severe patients. In fact these results were published in the media on June 4. The RECOVERY researchers severely overdosed and poisoned their patients with HCQ. Even with such overdoses of HCQ, no adverse cardiac events occurred, which is consistent with other clinical data. Continue reading NEJM Day: Boosting RDV, Attacking HCQ

Fauci Lied about Cross-Reactivity Study

Dr. Anthony Fauci brazenly lied to Senator Rand Paul, MD, when questioned about preexisting immunity to COVID-19, that some people have from coronavirus common colds. Existence of such cross-reactivity was not in doubt and was acknowledged by Dr. Fauci earlier. But on Wednesday, September 23, Dr. Fauci said “there was a study that recently came out that preexisting immunity to coronaviruses that are common cold do not cross-react with the covid-19”. Continue reading Fauci Lied about Cross-Reactivity Study

NIH Scientists Receive Royalties from Big Pharma

Under 15 U.S. Code § 3710c, federal researchers, whose work was patented and commercialized, receive royalties at the rate of at least 15% of what the US government receives from the licensees, capped at $150,000 per person, per year. NIH and CDC pay their scientists 25% (on amounts over $50,000). These royalties are paid even after the person leaves the government employment and continue after his or her death.

NIH, NIAID, or CDC researcher who contributed to the development of a novel drug or therapy, and was named as one of the inventors on a commercialized patent, may be entitled to $3 million in royalties over the 20-year lifespan of the patent.  Continue reading NIH Scientists Receive Royalties from Big Pharma